Fred Saad MD, FRCSProfessor and Chief of Urology, Director of GU Oncology, Raymond Garneau Chair in Prostate Cancer, University of Montreal Hospital Center (CHUM), Director, Prostate Cancer Research, Montreal Cancer Institute/CRCHUM, Montréal, Québec, Canada
Fred Saad MD FRCS, is Professor and Chief of Urology and Director of G-U Oncology at the University of Montreal Hospital Center (CHUM). He holds the Raymond Garneau Chair in Prostate Cancer Research and is Director of clinical research and the molecular oncology research laboratory in Prostate Cancer. He is an active member of CUA, AUA, ASCO, ESMO, AAGUS and has held several leadership positions such as is Past-President of the Canadian Urologic Association and Chair of the NCIC G-U Group and CUOG. Dr. Saad has played a leadership role and been a co-author on many of the practice changing clinical trials and publications in advanced prostate cancer over the last 20 years. He presently sits on 7 steering committees of ongoing international clinical trials and serves on several guideline committees. He is a member of several editorial boards, including Lancet Oncology, JAMA Oncology, Nature Urology, Genitourinary Cancer, CUAJ and Urology. He has published over 600 peer-reviewed articles and with an h-factor of 110 and over 55,000 citations he is listed as one of the world’s most cited clinician-scientists. Dr. Saad’s research interests include novel therapeutics in prostate cancer, molecular prognostic markers and mechanisms of progression. He has over 40 clinical and basic research projects ongoing and has received over 40 million dollars in research grants. His numerous awards include the lifetime achievement award from the CHUM Research Center, Lifetime Achievement Award from the Quebec Urologic Association and in 2018 was named a Knight of The National Order of Quebec, the highest honor given by the Quebec government.
DisclosuresDr. Saad discloses the following: Consultant, honoraria, advisory board member and research funding (institution): Astellas, Bayer, Janssen, Sanofi.
Recent Contributions to PracticeUpdate:
- Addition of Apalutamide vs Placebo to Abiraterone and Prednisone for the Treatment of Metastatic Castration-Resistant Prostate Cancer
- Indirect Comparisons of Efficacy Between Combination Approaches in Metastatic Hormone-Sensitive Prostate Cancer
- Radiotherapy and Short- vs Intermediate-Term Androgen Suppression ± Zoledronic Acid in Locally Advanced Disease
- Surgical vs Intermittent Castration for Prostate Cancer